References
- World Health Organization. Weekly Epidemiological Record - considerations for pneumococcal vaccination in older adults. Geneva: World Health Organization; 2021 [2023 Aug 7]. Available from: https://apps.who.int/iris/bitstream/handle/10665/341721/WER9623-eng-fre.pdf
- National Institute of Infectious Diseases. Infectious Agents Surveillance Report (IASR) - pathogenic microorganism detection information 2023. [2023 Nov 9]. Available from: https://www.niid.go.jp/niid/images/idsc/iasr/44/515.pdf
- Miyazaki T, Hirano K, Ichihara K, et al. Community-acquired pneumonia incidence in adults 18 years of age and older in Goto City, Japan: a prospective, population-based study. CHEST Pulmonary. 2023;1(2):100007. doi: 10.1016/j.chpulm.2023.100007
- Portal sSte of Official Statistics of Japan. Current population estimates. 2022 [2023 Nov 9]. Available from: https://www.stat.go.jp/english/data/jinsui/2022np/index.html#:~:text=The%20population%20under%2015%20years,percent%20of%20the%20total%20population
- Ministry of Health Labour and Welfare website. About pneumococcal vaccine PPSV23. 2018 [2023 Aug 8]. Available from: https://www.mhlw.go.jp/content/10601000/000342164.pdf
- Ministry of Health Labour and Welfare website. 58th health sciences council immunisation - basic Immunisation policy subcommittee of the subcommittee on vaccines document. 2020 [2024 Jan]. Available from: https://www.mhlw.go.jp/stf/newpage_36952.html
- Epidemiological information on invasive pneumococcal infections in children and adults. Current serotype distribution of adult IPD-derived pneumococci 2022. [2023 Aug 14]. Available from: https://ipd-information.com/?page_id=49
- Kawakami K, Nakamura A, Wakana A, et al. A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older. Hum Vaccin Immunother. 2020 Jul 2;16(7):1521–1528. doi: 10.1080/21645515.2019.1690332
- National Institute of Infectious Diseases. Infectious Agents Surveillance Report - pathogenic microorganism detection information 2018. [2023 Aug 16]. Available from: https://www.niid.go.jp/niid/images/idsc/iasr/39/461.pdf
- Ministry of Health Labour and Welfare - Health Insurance Bureau. Number of people receiving regular vaccinations 2021. [2024 Jan 5]. Available from: https://www.mhlw.go.jp/topics/bcg/other/5.html
- Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol. 2009 Mar;9(3):213–220. doi: 10.1038/nri2494
- Leidner AJ. Summary of three economic models evaluating pneumococcal vaccines in adults in the United States. In: ACIP Meeting: Centers for Disease Control and Prevention; 2021 [2024 Jan 4]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-09-29/02-Pneumococcal-Leidner-508.pdf
- National Institute of Infectious Diseases. 23-valent pneumococcal polysaccharide vaccine fact sheet. 2018 [2023 Aug 14]. Available from: https://www.mhlw.go.jp/file/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka/0000184910_1.pdf
- Patterson S, Webber C, Patton M, et al. A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia immunization Trial in Adults). Trials Vaccinol. 2016;5:92–96. doi: 10.1016/j.trivac.2016.04.004
- Suzuki M, Dhoubhadel BG, Ishifuji T, et al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis. 2017;17(3):313–321. doi: 10.1016/S1473-3099(17)30049-X
- Application for manufacturing and sales approval for precipitated 20-valent pneumococcal conjugate vaccine. Pfizer Inc.; 2023. Available from: https://www.pfizer.co.jp/pfizer/company//press/2023/2023-09-13-02.
- Essink B, Sabharwal C, Cannon K, et al. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years. Clin Infect Dis. [2022 Aug 31];75(3):390–398. doi: 10.1093/cid/ciab990
- Haranaka M, Young Song J, Huang KC, et al. A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan. Vaccine. 2024 Jan 23;42(5):1071–1077. doi: 10.1016/j.vaccine.2024.01.004
- Hurley D, Griffin C, Young M, et al. Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age. Clin Infect Dis. 2021 Oct 5;73(7):e1489–e1497. doi: 10.1093/cid/ciaa1045
- Klein NP, Peyrani P, Yacisin K, et al. A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. Vaccine. 2021 Sep 7;39(38):5428–5435. doi: 10.1016/j.vaccine.2021.07.004
- Hoshi SL, Shono A, Seposo X, et al. Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly. Vaccine. 2022 Nov 22;40(49):7057–7064. doi: 10.1016/j.vaccine.2022.10.010
- Mendes D, Averin A, Atwood M, et al. Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease. Expert Rev Pharmacoecon Outcomes Res. 2022 Dec;22(8):1285–1295. doi: 10.1080/14737167.2022.2134120
- Igarashi A, Hirose E, Kobayashi Y, et al. Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan. Expert Rev Vaccines. 2021 Sep;20(9):1153–1165. doi: 10.1080/14760584.2021.1952869
- Ikeda T. Research guidelines for evaluating the cost-effectiveness of vaccinations. Tokyo: Ministry of Health Labour and Welfare; 2017 [2024 Jan 4]. Available from: https://www.mhlw.go.jp/file/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka/0000184902_1.pdf
- Ministry of Health Labour and Welfare - Health Insurance Bureau. Cost-effectiveness evaluation of drugs, medical devices and regenerative medicine products. 2019 [2023 Nov 23]. Available from: https://www.mhlw.go.jp/content/000497467.pdf
- Portal Site of Official Statistics of Japan. Population Estimates Annual Report 2022. [2023 Aug 16]. Available from: https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&tclass1=000001011679&tclass2val=0
- Imai K, Petigara T, Kohn MA, et al. Risk of pneumococcal diseases in adults with underlying medical conditions: a retrospective, cohort study using two Japanese healthcare databases. BMJ Open. 2018 Mar 2;8(3):e018553. doi: 10.1136/bmjopen-2017-018553
- The JRS guidelines for the management of community acquired pneumonia in adults. Nihon Kokyuki Gakkai Zasshi. 2007 Jan 15;Suppl:2–85. https://pubmed.ncbi.nlm.nih.gov/17290540/
- Bridges CB, Coyne-Beasley T, Advisory Committee on Immunization Practices. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States, 2014. Ann Intern Med. 2014 Feb 4;160(3):190. doi: 10.7326/M13-2826
- Joint Committee on Vaccination and Immunisation. Statement on the wider use of pneumococcal conjugate vaccines in the UK. 2013 [cited 2023 Oct 11]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/224765/JCVI_statement_on_pneumococcal_vaccination_for_clinical_risk_groups_Final.pdf
- Ministry of Health Labour and Welfare website. Amendment of code of practice for immunization. 2014 [cited 2023 Dec 18]. Available from: https://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/0000121144.pdf
- JMDC Inc. JMDC Claims Database. [cited 2023 Aug 11]. Available from: https://www.jmdc.co.jp/en/
- Medical Data Vision Co. MDV Database. [cited 2023 Nov 9]. Available from: https://en.mdv.co.jp/
- National Institute of Infectious Diseases. Surveillance data - summary table list 2021. [2023 Nov 9]. Available from: https://www.niid.go.jp/niid/ja/allarticles/surveillance/2270-idwr/nenpou/11638-syulist2021.html
- Kobayashi K, Jo T, Mimura W, et al. Interrupted time-series analyses of routine vaccination program for elderly pneumonia patients in Japan; an ecological study using aggregated nationwide inpatient data. Hum Vaccin Immunother. 2021;17(8):2661–2669. doi: 10.1080/21645515.2021.1875760
- Nakashima K, Suzuki K, Aoshima M, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan. Vaccine. 2022 Nov 2;40(46):6589–6598. doi: 10.1016/j.vaccine.2022.09.055
- Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015 Mar 19;372(12):1114–1125. doi: 10.1056/NEJMoa1408544
- Mangen MJ, Rozenbaum MH, Huijts SM, et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015 Nov;46(5):1407–1416. doi: 10.1183/13993003.00325-2015
- French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med. 2010 Mar 4;362(9):812–822. doi: 10.1056/NEJMoa0903029
- Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349(14):1341–1348. doi: 10.1056/NEJMoa035060
- Djennad A, Ramsay ME, Pebody R, et al. Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and Wales. EClinicalMedicine. 2018 Dec;6:42–50. doi: 10.1016/j.eclinm.2018.12.007
- Boccalini S, Bechini A, Levi M, et al. Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy. Hum Vaccin Immunother. 2013 Mar;9(3):699–706. doi: 10.4161/hv.23268
- Cho BH, Stoecker C, Link-Gelles R, et al. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions. Vaccine. 2013 Dec 5;31(50):6011–6021. doi: 10.1016/j.vaccine.2013.10.024
- Evers SM, Ament AJ, Colombo GL, et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis. 2007 Aug;26(8):531–540. doi: 10.1007/s10096-007-0327-z
- Fry AM, Zell ER, Schuchat A, et al. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine. 2002 Dec 13;21(3–4):303–311. doi: 10.1016/S0264-410X(02)00451-6
- Heo JY, Seo YB, Choi WS, et al. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea. PLOS ONE. 2017;12(5):e0177342. doi: 10.1371/journal.pone.0177342
- Hoshi SL, Kondo M, Okubo I, et al. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan. PLOS ONE. 2015;10(10):e0139140. doi: 10.1371/journal.pone.0139140
- Johnstone J, Marrie TJ, Eurich DT, et al. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med. 2007 Oct 8;167(18):1938–1943. doi: 10.1001/archinte.167.18.1938
- Kuhlmann A, Theidel U, Pletz MW, et al. Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany. Health Econ Rev. 2012 Mar 30;2(1):4. doi: 10.1186/2191-1991-2-4
- Lawrence H, Pick H, Baskaran V, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study. PLOS Med. 2020;17(10):e1003326. doi: 10.1371/journal.pmed.1003326
- Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD000422. doi: 10.1002/14651858.CD000422.pub3
- Ortqvist A, Hedlund J, Burman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet. 1998 Feb 7;351(9100):399–403. doi: 10.1016/S0140-6736(97)07358-3
- Simberkoff MS, Cross AP, Al-Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986 Nov 20;315(21):1318–1327. doi: 10.1056/NEJM198611203152104
- Sisk JE, Whang W, Butler JC, et al. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med. 2003 Jun 17];138(12):960–968. doi: 10.7326/0003-4819-138-12-200306170-00007
- Smith KJ, Wateska AR, Nowalk MP, et al. Modeling of Cost Effectiveness of Pneumococcal Conjugate Vaccination Strategies in U.S. Older Adults. Am J Prev Med. 2013 Apr;44(4):373–381. doi: 10.1016/j.amepre.2012.11.035
- Stoecker C, Kim L, Gierke R, et al. Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States. J Gen Intern Med. 2016 Aug;31(8):901–908. doi: 10.1007/s11606-016-3651-0
- Stoecker C, Kobayashi M, Matanock A, et al. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program. Vaccine. 2020 Feb 11;38(7):1770–1777. doi: 10.1016/j.vaccine.2019.12.029
- Kuhne F, Achtert K, Puschner F, et al. Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany. Expert Rev Vaccines. 2023 Jan;22(1):921–932. doi: 10.1080/14760584.2023.2262575
- Cantarero D, Ocana D, Onieva-Garcia MA, et al. Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain. Vaccine. 2023 Aug 14;41(36):5342–5349. doi: 10.1016/j.vaccine.2023.07.016
- Marbaix S, Mignon A, Taelman A, et al. Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults. Expert Rev Vaccines. 2023 Jan;22(1):1008–1021. doi: 10.1080/14760584.2023.2273892
- Ministry of Health Labour and Welfare website. Overview of the 2020 simplified life table 2020. [2023 Sep]. Available from: https://www.mhlw.go.jp/toukei/saikin/hw/life/life22/index.html
- Chang B, Tamura K, Fujikura H, et al. Pneumococcal meningitis in adults in 2014-2018 after introduction of pediatric 13-valent pneumococcal conjugate vaccine in Japan. Sci Rep. 2022 Feb 23;12(1):3066. doi: 10.1038/s41598-022-06950-w
- Yanagihara K, Kosai K, Mikamo H, et al. Serotype distribution and antimicrobial susceptibility of streptococcus pneumoniae associated with invasive pneumococcal disease among adults in Japan. Int J Infect Dis. 2021 Jan;102:260–268. doi: 10.1016/j.ijid.2020.10.017
- Konomura K, Nagai H, Akazawa M. Economic burden of community-acquired pneumonia among elderly patients: a Japanese perspective. Pneumonia (Nathan). 2017;9(1):19. doi: 10.1186/s41479-017-0042-1
- Tashiro M, Fushimi K, Takazono T, et al. A mortality prediction rule for non-elderly patients with community-acquired pneumonia. BMC Pulm Med. 2016 Mar 8;16(1):39. doi: 10.1186/s12890-016-0199-z
- Shiroiwa T, Fukuda T, Ikeda S, et al. Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D. Qual Life Res. 2016 Mar;25(3):707–719. doi: 10.1007/s11136-015-1108-2
- Blommaert A, Hanquet G, Willem L, et al. Use of pneumococcal vaccines in the elderly: an economic evaluation (short report). KCE; 2016 [cited 2023 Dec 18]. Available from: https://kce.fgov.be/sites/default/files/2021-11/KCE_274C_Short-Report_Pneumococcal.pdf
- Glick HA, Miyazaki T, Hirano K, et al. One-Year Quality of Life Post-Pneumonia Diagnosis in Japanese Adults. Clin Infect Dis. [2021 Jul 15];73(2):283–290. doi: 10.1093/cid/ciaa595
- Ministry of Health Labour and Welfare. About pneumococcal vaccines for children 2023. [2024 Jan 4]. Available from: https://www.mhlw.go.jp/content/10900000/001139474.pdf
- Ministry of Health Labour and Welfare website. NHI price revisions - partial revision of drug prices (medicine price standards) for drugs used. 2023 Oct 11. Available from: https://www.mhlw.go.jp/content/12404000/001065988.pdf
- Centers for Disease Control and Prevention website. Vaccines for Children Program (VFC). CDC Vaccine Price List. 2023 [2023 Nov 9]. Available from: https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html
- Ministry of Health Labour and Welfare website. Methods for cost-effectiveness estimation for vaccination - medical fees 2022. [2023 Aug 8]. Available from: https://www.mhlw.go.jp/content/12404000/000907834.pdf
- Fukuda H, Onizuka H, Nishimura N, et al. Risk factors for pneumococcal disease in persons with chronic medical conditions: Results from the LIFE Study. Int J Infect Dis. 2022 Mar;116:216–222. doi: 10.1016/j.ijid.2021.12.365
- Portal Site of Official Statistics of Japan. Labour force survey 2022. [2023 Aug 16]. Available from: https://www.stat.go.jp/data/roudou/sokuhou/nen/ft/pdf/index1.pdf
- Ministry of Health Labour and Welfare website. Number of people certified for long-term Care/Support need. 2021 [2023 Sep]. Available from: https://www.mhlw.go.jp/topics/kaigo/osirase/jigyo/20/dl/r02_gaiyou.pdf
- Portal Site of Official Statistics of Japan. Wage Structure Basic Statistical Survey (general worker/Industrial classification) 2022. [2023 Oct 11]. Available from: https://www.e-stat.go.jp/stat-search/files?page=1&layout=datalist&toukei=00450091&tstat=000001011429&cycle=0&tclass1=000001202310&tclass2=000001202312&tclass3=000001202328&tclass4val=0
- Morimoto K, Suzuki M, Ishifuji T, et al. The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study. PLOS ONE. 2015;10(3):e0122247. doi: 10.1371/journal.pone.0122247
- Pfizer Inc. Application for manufacturing and sales approval for precipitated 20-valent pneumococcal conjugate vaccine. 2023 [2023 Dec 19]. Available from: https://www.pfizer.co.jp//pfizer/company/press/2023/2023-09-13-02
- National Institute of Infectious Diseases. Fact sheet on pneumococcal conjugate vaccine for children. Ministry of Health Labour and Welfare. 2010 [2023 Aug 16]. Available from: https://www.mhlw.go.jp/file/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka/0000207087_1.pdf
- Malene BM, Oyvind H, Tor M, et al. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting. Cost Eff Resour Alloc. 2023 Aug 9;21(1):52. doi: 10.1186/s12962-023-00458-4
- Olsen J, Schnack H, Skovdal M, et al. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23. J Med Econ. 2022 Jan;25(1):1240–1254. doi: 10.1080/13696998.2022.2152235
- Mohapi L, Pinedo Y, Osiyemi O, et al. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV. AIDS. 2022 Mar 1;36(3):373–382. doi: 10.1097/QAD.0000000000003126
- Bornheimer R, Shea KM, Sato R, et al. Risk of exacerbation following pneumonia in adults with heart failure or chronic obstructive pulmonary disease. PLOS ONE. 2017;12(10):e0184877. doi: 10.1371/journal.pone.0184877
- Campling J, Jones D, Chalmers J, et al. Clinical and financial burden of hospitalised community-acquired pneumonia in patients with selected underlying comorbidities in England. BMJ Open Respir Res. 2020 Oct;7(1):e000703. doi: 10.1136/bmjresp-2020-000703
- Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015 Jan 20;313(3):264–274. doi: 10.1001/jama.2014.18229
- Hughes GJ, Wright LB, Chapman KE, et al. Serotype-specific differences in short- and longer-term mortality following invasive pneumococcal disease. Epidemiol Infect. 2016 Sep;144(12):2654–2669. doi: 10.1017/S0950268816000856
- Myint PK, Hawkins KR, Clark AB, et al. Long-term mortality of hospitalized pneumonia in the EPIC-Norfolk cohort. Epidemiol Infect. 2016 Mar;144(4):803–809. doi: 10.1017/S0950268815001971